A Study of LY3866288 in Healthy Participants
Completed · Phase 1 · NCT06641037
Conditions: Healthy
At a glance
- Research payments reported, 2025
- $491,130
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 15
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3866288 (drug)
- Dates
- Started 2024-10-17; completion 2024-12-02
- Results posted
- Not yet
The purpose of this study is to evaluate how well LY3866288 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to check how much LY3866288 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 9 weeks including screening.
From ClinicalTrials.gov, last updated 2025-04-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $491,130 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research LP Dallas $491,130
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.